This page houses the business plan for Innovative Potential.

​​

You will need to accept the following three (3) operational contexts before proceeding to the business plan:
 

1. Legally: Innovative Potential behaves closest to an international treaty or independent state corporation for electroactivated chemotherapy, intratumor injection, and or the chemotherapeutic galvanostat/potentiostat; and,
    

2. Internet: Innovative Potential is a biomedical first-principles entity. Innovative Potential exists unilaterally and ubiquitiously everywhere first-and-foremost with respect to the chemotherapeutic galvanostat/potentiostat; and,
    

3. Financially: Because of the plethora of planetary-firsts derived from Innovative Potential and its technologies: it is fundamentally incorrect to apply a revenue-based business model to Innovative Potential. Innovative Potential is a value model entity.
   ​

Additionally: Innovative Potential is:
 

• An internationally recognized and entreatied company via the Patent Cooperation Treaty; and,
   

• A federally-recognized and legal monopoly of Canada and the United States of America; and,
   

• Granted patented and exclusivized market powers from: 2017-2038, in both Canada and the United States; and,
   

• Internationally cross-licensed through a set of exclusive licensing agreements for the sharing and proliferation of intellectual property, including patents.